JP7304892B2 - 抗増殖性化合物およびその使用 - Google Patents
抗増殖性化合物およびその使用 Download PDFInfo
- Publication number
- JP7304892B2 JP7304892B2 JP2020559394A JP2020559394A JP7304892B2 JP 7304892 B2 JP7304892 B2 JP 7304892B2 JP 2020559394 A JP2020559394 A JP 2020559394A JP 2020559394 A JP2020559394 A JP 2020559394A JP 7304892 B2 JP7304892 B2 JP 7304892B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- nitrogen
- acceptable salt
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023092450A JP2023101824A (ja) | 2018-04-24 | 2023-06-05 | 抗増殖性化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661719P | 2018-04-24 | 2018-04-24 | |
| US62/661,719 | 2018-04-24 | ||
| PCT/US2019/028607 WO2019209759A1 (en) | 2018-04-24 | 2019-04-23 | Antiproliferation compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092450A Division JP2023101824A (ja) | 2018-04-24 | 2023-06-05 | 抗増殖性化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522242A JP2021522242A (ja) | 2021-08-30 |
| JP2021522242A5 JP2021522242A5 (https=) | 2022-04-13 |
| JP7304892B2 true JP7304892B2 (ja) | 2023-07-07 |
Family
ID=66655429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559394A Active JP7304892B2 (ja) | 2018-04-24 | 2019-04-23 | 抗増殖性化合物およびその使用 |
| JP2023092450A Pending JP2023101824A (ja) | 2018-04-24 | 2023-06-05 | 抗増殖性化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023092450A Pending JP2023101824A (ja) | 2018-04-24 | 2023-06-05 | 抗増殖性化合物およびその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10815225B2 (https=) |
| EP (2) | EP3784666B1 (https=) |
| JP (2) | JP7304892B2 (https=) |
| KR (1) | KR102813581B1 (https=) |
| CN (1) | CN112236428B (https=) |
| AR (1) | AR114496A1 (https=) |
| AU (1) | AU2019261308B2 (https=) |
| BR (1) | BR112020020940A2 (https=) |
| CA (1) | CA3098335A1 (https=) |
| CY (1) | CY1125433T1 (https=) |
| DK (2) | DK4043460T3 (https=) |
| ES (2) | ES2987356T3 (https=) |
| FI (1) | FI4043460T3 (https=) |
| HR (2) | HRP20241163T1 (https=) |
| HU (2) | HUE058746T2 (https=) |
| IL (2) | IL278142B2 (https=) |
| LT (1) | LT3784666T (https=) |
| MX (1) | MX2020011089A (https=) |
| PL (2) | PL3784666T3 (https=) |
| PT (2) | PT3784666T (https=) |
| RS (1) | RS63281B1 (https=) |
| SG (1) | SG11202009500QA (https=) |
| SI (1) | SI3784666T1 (https=) |
| SM (1) | SMT202200308T1 (https=) |
| TW (1) | TWI813673B (https=) |
| WO (1) | WO2019209759A1 (https=) |
| ZA (1) | ZA202006071B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20241163T1 (hr) | 2018-04-24 | 2024-11-22 | Merck Patent Gmbh | Antiproliferacijski spojevi i njihova uporaba |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020236834A1 (en) * | 2019-05-20 | 2020-11-26 | Seshadri Raju | Modified z stents for iliac vein stenting |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
| WO2024073502A1 (en) * | 2022-09-28 | 2024-04-04 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
| TW202547516A (zh) * | 2024-04-26 | 2025-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 稠合雙環化合物及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526260A (ja) | 2008-07-03 | 2011-10-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロロピリジニルピリミジン−２−イルアミン誘導体 |
| JP2012522724A (ja) | 2009-04-02 | 2012-09-27 | 田辺三菱製薬株式会社 | ３−［１，４］オキサゼパン−４−ピリミドン誘導体 |
| JP2013512272A (ja) | 2009-12-04 | 2013-04-11 | エフ．ホフマン−ラ ロシュ アーゲー | モノアミン再取り込み阻害剤としてのジフェニルアゼピン誘導体 |
| JP2018505197A (ja) | 2015-02-13 | 2018-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | がんの処置において使用するためのピリミジン誘導体 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| DE60037345T2 (de) | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| PT1536827E (pt) | 2002-08-14 | 2009-03-20 | Silence Therapeutics Ag | Utilização de proteína cinase n beta |
| AU2004228668B2 (en) | 2003-04-03 | 2011-10-27 | Park Funding, Llc | PI-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1692153A4 (en) | 2003-07-03 | 2007-03-21 | Univ Pennsylvania | INHIBITION OF EXPRESSION OF SYK-KINASE |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| KR101566840B1 (ko) | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CA2729045A1 (en) | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| HRP20241163T1 (hr) | 2018-04-24 | 2024-11-22 | Merck Patent Gmbh | Antiproliferacijski spojevi i njihova uporaba |
-
2019
- 2019-04-23 HR HRP20241163TT patent/HRP20241163T1/hr unknown
- 2019-04-23 DK DK22161962.0T patent/DK4043460T3/da active
- 2019-04-23 ES ES22161962T patent/ES2987356T3/es active Active
- 2019-04-23 HR HRP20220710TT patent/HRP20220710T1/hr unknown
- 2019-04-23 BR BR112020020940-6A patent/BR112020020940A2/pt active Search and Examination
- 2019-04-23 KR KR1020207033873A patent/KR102813581B1/ko active Active
- 2019-04-23 SM SM20220308T patent/SMT202200308T1/it unknown
- 2019-04-23 AR ARP190101062A patent/AR114496A1/es unknown
- 2019-04-23 PT PT197267925T patent/PT3784666T/pt unknown
- 2019-04-23 SI SI201930251T patent/SI3784666T1/sl unknown
- 2019-04-23 US US16/391,419 patent/US10815225B2/en active Active
- 2019-04-23 PT PT221619620T patent/PT4043460T/pt unknown
- 2019-04-23 LT LTEPPCT/US2019/028607T patent/LT3784666T/lt unknown
- 2019-04-23 IL IL278142A patent/IL278142B2/en unknown
- 2019-04-23 MX MX2020011089A patent/MX2020011089A/es unknown
- 2019-04-23 WO PCT/US2019/028607 patent/WO2019209759A1/en not_active Ceased
- 2019-04-23 AU AU2019261308A patent/AU2019261308B2/en active Active
- 2019-04-23 JP JP2020559394A patent/JP7304892B2/ja active Active
- 2019-04-23 TW TW108114146A patent/TWI813673B/zh active
- 2019-04-23 IL IL301501A patent/IL301501B2/en unknown
- 2019-04-23 FI FIEP22161962.0T patent/FI4043460T3/fi active
- 2019-04-23 HU HUE19726792A patent/HUE058746T2/hu unknown
- 2019-04-23 CA CA3098335A patent/CA3098335A1/en active Pending
- 2019-04-23 ES ES19726792T patent/ES2919572T3/es active Active
- 2019-04-23 EP EP19726792.5A patent/EP3784666B1/en active Active
- 2019-04-23 SG SG11202009500QA patent/SG11202009500QA/en unknown
- 2019-04-23 PL PL19726792.5T patent/PL3784666T3/pl unknown
- 2019-04-23 CN CN201980036896.XA patent/CN112236428B/zh active Active
- 2019-04-23 EP EP22161962.0A patent/EP4043460B1/en active Active
- 2019-04-23 DK DK19726792.5T patent/DK3784666T3/da active
- 2019-04-23 RS RS20220537A patent/RS63281B1/sr unknown
- 2019-04-23 HU HUE22161962A patent/HUE067936T2/hu unknown
- 2019-04-23 PL PL22161962.0T patent/PL4043460T3/pl unknown
-
2020
- 2020-08-27 US US17/004,109 patent/US11440907B1/en active Active
- 2020-09-30 ZA ZA2020/06071A patent/ZA202006071B/en unknown
-
2022
- 2022-06-10 CY CY20221100409T patent/CY1125433T1/el unknown
- 2022-09-07 US US17/930,352 patent/US12195453B2/en active Active
-
2023
- 2023-06-05 JP JP2023092450A patent/JP2023101824A/ja active Pending
-
2024
- 2024-11-08 US US18/941,447 patent/US20250188070A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526260A (ja) | 2008-07-03 | 2011-10-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピロロピリジニルピリミジン−２−イルアミン誘導体 |
| JP2012522724A (ja) | 2009-04-02 | 2012-09-27 | 田辺三菱製薬株式会社 | ３−［１，４］オキサゼパン−４−ピリミドン誘導体 |
| JP2013512272A (ja) | 2009-12-04 | 2013-04-11 | エフ．ホフマン−ラ ロシュ アーゲー | モノアミン再取り込み阻害剤としてのジフェニルアゼピン誘導体 |
| JP2018505197A (ja) | 2015-02-13 | 2018-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | がんの処置において使用するためのピリミジン誘導体 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11780837B2 (en) | CXCR4 inhibitors and uses thereof | |
| JP7304892B2 (ja) | 抗増殖性化合物およびその使用 | |
| US20210363139A1 (en) | Cxcr4 inhibitors and uses thereof | |
| EP3846793B1 (en) | Eif4e inhibitors and uses thereof | |
| US20240174665A1 (en) | Cdk2 inhibitors and uses thereof | |
| HK40078355B (en) | Antiproliferation compounds and uses thereof | |
| HK40078355A (en) | Antiproliferation compounds and uses thereof | |
| RU2811969C2 (ru) | Антипролиферативные соединения и их применения | |
| HK40047065B (en) | Antiproliferation compounds and uses thereof | |
| HK40047065A (en) | Antiproliferation compounds and uses thereof | |
| WO2024264070A2 (en) | Akt inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220405 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230315 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230605 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230616 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230627 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7304892 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |